Addex Therapeutics Ltd (ADXN) Monday said its Phase 2 epilepsy study of ADX71149 in patients with focal onset seizures with suboptimal response to antiepileptic drugs levetiracetam or brivaracetam did not meet primary goal.
The study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
For comments and feedback contact: editorial@rttnews.com
Business News